Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | 12-week pill that cures hepatitis C. | Backbone drug for HIV treatment, PrEP and hepatitis B. |
| Body system | Antivirals | Antivirals |
| Drug class | Hepatitis C direct-acting antivirals | Nucleos(t)ide reverse transcriptase inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | Chronic hepatitis C (all genotypes) | HIV treatment, HIV pre-exposure prophylaxis (PrEP, with emtricitabine), Chronic hepatitis B |
| How it works | Blocks two proteins the hepatitis C virus needs to copy itself. | A fake DNA building block that stops HIV and hepatitis B copying themselves. |
| Starts working | — | — |
| Half-life | About 15 hours (velpatasvir) | About 17 hours in plasma |
| Typical adult dose | One tablet (400/100 mg) once a day for 12 weeks. | 300 mg (245 mg tenofovir disoproxil) once a day. |
| Forms | Tablet | Tablet, Combination tablets |
| Common side effects | Headache, Tiredness, Nausea | Nausea, Diarrhoea, Headache, Dizziness |
| Serious side effects | Severe slow heart rate with amiodarone, Hepatitis B reactivation | Kidney damage, Bone thinning, Hepatitis B flare if stopped suddenly |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Use with cautionNot routinely used in pregnancy yet; data emerging. | Generally considered safeWidely used in pregnancy for HIV and hepatitis B. |
| Breastfeeding | — | — |
| In use since | 2016 | 2001 |
| Brand names | United States: EpclusaUnited Kingdom: EpclusaIndia: Velpanat, Myhep All | United States: Viread, Truvada (with emtricitabine)United Kingdom: Viread, TruvadaIndia: Tenvir |
| Legal status | — | — |
| ATC code | J05AP55 | J05AF07 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker